Dr Alex Tatem: A urologist specializing in men's health (low testosterone, erectile dysfunction, male fertility) who runs a popular YouTube channel educating the public on peptides and hormone therapy.
What this episode covers
Steven Bartlett sits down with urologist Dr Alex Tatem for a deep dive on peptides: short chains of amino acids that act as targeted 'keys' for specific receptors in the body. Tatem walks through specific compounds (BPC-157, TB-500, GHK-Cu, the GLP-1 drugs semaglutide and tirzepatide, growth-hormone secretagogues and more), what each does, and the safety trade-offs. He explains the regulatory backstory: how a 2013 gene-patent ruling and a compounding-pharmacy scandal led to peptides being banned in 2023, and how the FDA is now considering moving seven peptides back to a legal, compoundable category in July. The conversation covers the gray market, GLP-1 weight loss and muscle preservation, declining male fertility, the Enhanced Games, and ends with Tatem's emotional account of his brutal surgical training and his work placing penile implants.
Also referenced (named, not recommended)
Mounjaro
Eli Lilly
“this is a prescription Mounjaro pen. So, Mounjaro is the brand name for tirzepatide, all right? Tirzepatide being the leading GLP-1 product right now from Lilly”— Dr Alex Tatem
Ozempic
Novo Nordisk
“This is like the Ozempic thing everyone's been talking about.”— Steven Bartlett
Viagra
Pfizer
“they eventually get to a point where things like Viagra and Cialis do not work. All right? And that is a dark place to be as a guy”— Dr Alex Tatem
Cialis
Eli Lilly
“they eventually get to a point where things like Viagra and Cialis do not work. All right? And that is a dark place to be as a guy”— Dr Alex Tatem
Zyn
Swedish Match
“They'll drink caffeine, you know, they'll, you know, pop a Zyn in their mouth, you know, and they'll try to tweak whatever variable they possibly can”— Dr Alex Tatem
Big reveals from this episode
- Tatem ties the peptide ban to the 2013 Myriad Genetics Supreme Court ruling that natural genes/compounds can't be patented, removing pharma's incentive to develop them.
- In 2023 the FDA moved 19 popular peptides from the legal 'category one' to banned 'category two' overnight.
- Says RFK Jr. has characterized the 2023 peptide ban as illegal.
- Agrees '110%' that big pharma didn't want peptides in regular people's hands because they can't patent them.
- Reports an FDA press release that in July it will consider returning seven peptides (including BPC-157) to legal status.
- Claims FDA commissioner Marty Makary has tweeted more about cracking down on compounded GLP-1s than about diabetes or heart disease combined.
- Tatem opens up that grueling surgical training left him with low testosterone and a near-breakdown after a patient lost a kidney.
- Reveals he has personally placed 1,100-1,200 penile implants, a 13-minute procedure.
Worth remembering
- Insulin, isolated in 1921, was the first peptide used in medicine.
- In animal studies BPC-157 healed fully transected Achilles tendons in rats, and its dose is so safe researchers haven't found the level that harms even 1% of subjects.
- A patient who lost 100 lb on tirzepatide saw his sperm count increase tenfold into the normal range.
- Revenue from semaglutide and tirzepatide alone is projected over $55 billion this year, approaching the combined revenue of the top four AI/LLM companies.
- Melanotan II produces a deep tan with minimal UV exposure and also causes strong erections; its derivative PT-141 (bremelanotide) is an approved prescription drug.
- Retatrutide, a triple-receptor GLP-1 drug, has produced 20-25% total body weight loss and Tatem predicts it will be a trillion-dollar drug owned solely by Lilly.
- Total sperm counts in young men have fallen dramatically since 1973, illustrated with vials of progressively clearer water.
- The Enhanced Games (Las Vegas, May 21-24) lets athletes openly use performance-enhancing drugs, offering $250K to winners and $1M for world records.
- There are 30 million men with erectile dysfunction in the US, more than the population of Australia, and oral ED drugs fail the first time for 15% of them.
- GHK-Cu is a copper tripeptide that declines with age and, applied topically, boosts collagen and elastin to improve skin.